<DOC>
	<DOCNO>NCT00333775</DOCNO>
	<brief_summary>This study evaluate efficacy safety 2 dos Avastin combination docetaxel , versus docetaxel plus placebo , patient metastatic HER2 negative breast cancer candidate taxane-based chemotherapy receive prior chemotherapy metastatic disease . The anticipated time treatment 1-2 year target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Bevacizumab ( Avastin ) Women With HER2 Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Five participant randomize docetaxel 100 mg/m^2 plus placebo group actually receive docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg include docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg group adverse event result . Sixteen participant randomize docetaxel 100 mg/m^2 plus placebo group actually receive docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg include docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg group adverse event result .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criterion : Female patient â‰¥ 18 year age . Human epidermal growth factor receptor 2 ( HER2 ) negative cancer breast locally recurrent metastatic disease , suitable chemotherapy . No adjuvant chemotherapy within 6 month randomization , taxanebased chemotherapy within 12 month randomization . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Exclusion criterion : Previous chemotherapy metastatic locally recurrent breast cancer . Radiotherapy treatment metastatic disease . Other primary tumor within last 5 year , except control limited basal cell squamous cancer skin , cancer situ cervix . Spinal cord compression brain metastasis . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomization . Inadequate bone marrow , liver , renal function . Uncontrolled hypertension .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>